DEPO-PROVERA®

Why Practitioners Choose DEPO-PROVERA®

Quarterly dosing can make adherence easier. A single DMPA injection provides contraceptive protection for about 12 weeks, with product labeling allowing administration at 13-week intervals. For patients who have difficulty taking a daily pill consistently, a clinician-administered injection reduces reliance on day-to-day adherence and incorporates contraceptive management into scheduled follow-up visits. DEPO-PROVERA® is also estrogen-free. As a progestin-only injectable, it may be considered for selected patients who cannot use estrogen-containing contraceptives, including some individuals with migraine with aura or certain thrombotic risk factors. Eligibility should always be assessed according to current clinical guidance and the patient’s individual medical history.

Contact Med Supply Solutions About DEPO-PROVERA®

Healthcare professionals seeking information about DEPO-PROVERA® can reach out to the Med Supply Solutions support team for details on availability, wholesale pricing, and shipping. Staff can assist licensed clinics with product inquiries related to medroxyprogesterone acetate injection.

What Is DEPO-PROVERA® Used For?

DEPO-PROVERA® CI is FDA-approved for prevention of pregnancy in women of reproductive potential. Medroxyprogesterone acetate is also approved in other formulations for the management of endometriosis-associated pain and, at higher-concentration dosing, for adjunctive or palliative treatment of endometrial and renal carcinoma — indications that the current 150mg/mL CI formulation does not carry. [1] DEPO-PROVERA® prevents pregnancy primarily by suppressing gonadotropin release and inhibiting ovulation. It also thickens cervical mucus and alters the endometrium, creating additional barriers to conception. Like other hormonal contraceptives, it does not protect against HIV or other sexually transmitted infections.[1] In clinical studies, the U.S. prescribing information reported 0.3 pregnancies per 100 women-years.[1] Effectiveness in routine practice depends on receiving repeat injections on schedule and maintaining appropriate follow-up.

DEPO-PROVERA® Indications & Patient Selection

DEPO-PROVERA® CI may be considered for patients seeking a reversible contraceptive that does not require daily administration. It can be incorporated into OB/GYN, women’s health, and primary care settings where regular follow-up every three months is practical. Before treatment begins, pregnancy should be excluded and the timing of the first injection confirmed. According to the product labeling, the initial dose should be administered within the first five days of a normal menstrual period, within five days after delivery for patients who are not breastfeeding, or at six weeks postpartum for those who are breastfeeding.[1] Delayed return to fertility is one of the most clinically important counseling points for this method. The prescribing information reports a median time to conception of approximately 10 months after the last injection, and some patients may take longer. This should be discussed with patients before initiation, not only at discontinuation. [1] Administration summary:

• DEPO-PROVERA® CI is administered as a 150 mg/mL deep intramuscular injection into the gluteal or deltoid muscle.
• Repeat injections are given every 12 to 13 weeks. Keeping each dose on schedule is essential for maintaining contraceptive coverage.
• Pregnancy should be excluded before initiation, and the first injection should be timed according to the approved product labeling.

DEPO-PROVERA® Safety Profile

FDA Boxed Warning — Bone Mineral Density Loss: Prolonged use of DEPO-PROVERA® may result in significant loss of bone mineral density. BMD loss is greater with increasing duration of use and may not be completely reversible after discontinuation. The prescribing information states that use beyond 2 years should be considered only when other contraceptive methods are inadequate. [1] Common side effects include menstrual irregularities or amenorrhea, weight changes, headache, mood changes, abdominal pain, dizziness, reduced libido, and injection-site reactions. In clinical practice, changes in bleeding patterns and body weight are often among the main topics addressed during patient counseling. Contraindications include known or suspected pregnancy, unexplained vaginal bleeding, known or suspected breast cancer, active thrombophlebitis or a current or previous thromboembolic disorder, significant liver disease, and hypersensitivity to medroxyprogesterone acetate or any component of the product.[1] Counseling about the return of fertility should be clear and realistic. Patients should not be told to expect menstrual cycles or fertility to resume immediately after discontinuation. The median time to conception is approximately 10 months after the last injection, although recovery varies among individuals.[1]

About DEPO-PROVERA®

DEPO-PROVERA® CI is a Pfizer product historically associated with Upjohn. The name refers specifically to medroxyprogesterone acetate injectable suspension, supplied at a concentration of 150 mg/mL for intramuscular administration. Pfizer also markets DEPO-SUBQ PROVERA 104®, a separate 104 mg/0.65 mL subcutaneous formulation with its own administration requirements and product labeling. Medroxyprogesterone acetate received its first FDA approval in 1959. DEPO-PROVERA® CI was approved in the United States as a contraceptive injection in October 1992 and is widely used internationally, appearing on the World Health Organization's Essential Medicines List. [1][3]

DEPO-PROVERA® vs Other Contraceptive Methods

DEPO-PROVERA® may be particularly useful for patients who prefer an estrogen-free contraceptive administered every three months and who may not be well suited to daily oral contraception or intrauterine device placement. Compared with combined oral contraceptives, DEPO-PROVERA® eliminates daily adherence requirements and avoids estrogen exposure. The trade-off is a longer delay to fertility return and the bone density warning — factors that do not apply to short-cycle oral methods. The NEXPLANON® implant provides contraception for up to 3 years and requires only one insertion and one removal procedure over that period. DEPO-PROVERA® may suit patients who prefer an injectable method over an implant but are willing to attend quarterly follow-up visits. The MIRENA® hormonal IUD provides long-acting intrauterine contraception for up to eight years. For patients who prefer not to use an intrauterine device or are not suitable candidates for placement, DEPO-PROVERA® offers a practical progestin-only alternative. For patients requiring a hormone-free option, SMB® copper IUDs avoid systemic progestin exposure entirely. They require intrauterine placement, while DEPO-PROVERA® is administered by injection — the choice turns on patient preference and clinical eligibility for an intrauterine device.

DEPO-PROVERA® Regulatory Status

DEPO-PROVERA® CI received FDA approval for contraception in October 1992. In 2004, a Boxed Warning regarding loss of bone mineral density was added and remains part of the current prescribing information.[1] The product is available by prescription only and is intended for administration by licensed health care professionals. DMPA is approved in many countries, but indications, formulations, and prescribing requirements differ by market. Practitioners should therefore confirm the applicable local regulatory status before procurement or clinical use.

FAQs

What is DEPO-PROVERA® and how does it work?

DEPO-PROVERA® CI is a depot medroxyprogesterone acetate contraceptive injection that works primarily by suppressing ovulation, while also thickening cervical mucus and producing endometrial changes that further reduce the likelihood of pregnancy. [1]

How often is DEPO-PROVERA® administered?

DEPO-PROVERA® CI is given as a 150mg/mL deep intramuscular injection every 12–13 weeks; timely repeat dosing is essential to maintain contraceptive coverage.

Does DEPO-PROVERA® affect bone density?

Yes — DEPO-PROVERA® carries an FDA Boxed Warning that prolonged use may cause significant bone mineral density loss, that this loss increases with duration of use, and that it may not be completely reversible. Use beyond 2 years is recommended only when other contraceptive methods are inadequate. [1]

How long does it take for fertility to return after stopping DEPO-PROVERA®?

Return to fertility may be delayed; the prescribing information reports a median time to conception of approximately 10 months after the last injection, and some patients may take longer. [1]

Is DEPO-PROVERA® suitable for patients who cannot take estrogen?

DEPO-PROVERA® is a progestin-only injection, so it may be an appropriate option for selected patients in whom estrogen-containing contraceptives are contraindicated. Patient selection should follow current medical eligibility criteria and individual risk assessment.

How can licensed professionals obtain information about DEPO-PROVERA®?

Licensed healthcare professionals may contact the Med Supply Solutions support team for general information about DEPO-PROVERA®.

Citations and Resources

[1] FDA. DEPO-PROVERA CI (medroxyprogesterone acetate) injectable suspension, for intramuscular use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020246s074lbl021583s045lbl.pdf. [2] Pfizer Medical Information. DEPO-PROVERA® CI product information. https://www.pfizermedical.com/depo-provera [3] World Health Organization. Medical eligibility criteria for contraceptive use, 6th ed. Published November 3, 2025. https://www.who.int/publications/i/item/9789240115583 For licensed healthcare professionals only. The content of this page is provided for informational purposes and does not constitute medical advice.